Emollients & Moisturisers

1. Clinical Overview

Summary

Emollients are medical moisturisers that form the cornerstone of therapy for all dry skin conditions including atopic dermatitis (eczema), psoriasis, ichthyosis, and xerosis. Unlike cosmetic moisturisers, emollients are therapeutic agents designed to restore and maintain skin barrier function through three principal mechanisms: occlusion (preventing transepidermal water loss), humectancy (attracting water into the stratum corneum), and lipid replacement (filling intercellular spaces). [1,2]

Proper emollient therapy significantly reduces disease severity, improves quality of life, and demonstrates important steroid-sparing effects—reducing the need for potent topical corticosteroids and systemic immunosuppressive agents. [3,4] Despite their fundamental importance, emollients remain widely under-prescribed, with many patients receiving inadequate quantities to achieve therapeutic benefit. [5]

Key Therapeutic Principles

1. Quantity Matters: Adult patients with moderate-to-severe atopic dermatitis require approximately 500g per week of emollient for whole-body application. [6]

2. Frequency Over Formulation: Regular, liberal application (minimum twice daily) is more important than the specific emollient chosen. [7]

3. Patient Preference Predicts Adherence: The most effective emollient is the one the patient will actually use. Trial of multiple formulations is standard practice. [8]

4. Soap Substitution is Mandatory: In eczematous conditions, conventional soaps and detergents must be completely replaced with emollient wash products. [9]

5. Long-term Maintenance: Emollients are not "treatment courses" but lifelong barrier support for patients with chronic inflammatory dermatoses. [10]

Clinical Pearls

The Fire Risk: ALL emollients (not just paraffin-based products) can act as accelerants when absorbed into fabrics. Clothing, bedding, and dressings become saturated with residue over time, creating severe fire hazards near ignition sources (cigarettes, candles, heaters). Multiple deaths have been documented in the UK, leading to MHRA Drug Safety Updates requiring prominent warnings on all emollient packaging. [11,12] The risk persists even after washing clothes at temperatures below 50°C.

Direction of Hair Growth: Always apply emollient in downward strokes following the direction of hair growth. Circular rubbing or upward application forces occlusive substances into hair follicles, occluding the follicular ostia and causing irritant/acne-form folliculitis (commonly misdiagnosed as bacterial infection). [13]

Soap Substitute Logic: Conventional soaps are alkaline (pH 9-10) and contain surfactants that strip lipids from the stratum corneum, disrupting the acid mantle (pH 4.5-5.5) essential for barrier function and antimicrobial defense. Using emollients as soap substitutes simultaneously cleanses skin while depositing protective lipids. [14]

The 30-Minute Rule: When using both emollients and topical corticosteroids, apply emollient FIRST, wait 30 minutes, then apply steroid. This prevents dilution of the corticosteroid and unwanted spread to unaffected skin areas. Historical "steroid first" advice has been superseded by pharmacokinetic studies. [15]

Pump vs Tub Dispensing: Tub packaging (while cheaper) becomes contaminated with bacteria (particularly Staphylococcus aureus and Pseudomonas aeruginosa) within days of use, potentially causing recurrent skin infections. Pump dispensers maintain sterility and are preferred for immunocompromised patients. [16]

---

2. Epidemiology and Clinical Context

Indications for Emollient Therapy

Prescribing Burden and Under-Treatment

A major systematic review of emollient prescribing in UK primary care revealed that:

• 68% of patients with documented eczema received less than the recommended minimum quantity
• Mean prescription quantity: 180g/month (vs. recommended 2000g/month for moderate disease)
• Under-prescribing was associated with increased topical corticosteroid use and higher rates of infection requiring antibiotics [5]

Recommended Quantities (NICE CG57 Guidance): [6]

---

3. Pathophysiology and Mechanisms of Action

Skin Barrier Structure

The stratum corneum functions as a lipid-enriched "brick and mortar" structure:

• Bricks: Terminally differentiated corneocytes (keratin-filled cells)
• Mortar: Intercellular lipid lamellae (ceramides, cholesterol, free fatty acids)

In inflammatory dermatoses, this barrier is disrupted through:

1. Genetic defects: Filaggrin mutations (present in 30% of atopic dermatitis patients) impair corneocyte integrity [1]
2. Enzymatic dysfunction: Abnormal lipid processing enzymes reduce ceramide production
3. Inflammation: Cytokines (IL-4, IL-13, IL-31) directly damage tight junctions and lipid synthesis
4. Environmental: Detergents, low humidity, friction accelerate lipid loss

This results in:

• Increased TEWL (Transepidermal Water Loss): 2-3× higher than normal skin
• Xerosis: Clinically dry, rough, flaky skin
• Pruritus: Via activation of itch-specific C-fibers
• Antigen penetration: Facilitates allergic sensitization

Three Mechanisms of Emollient Action

1. Occlusion (Preventing Water Loss)

Occlusive agents form a hydrophobic film on the skin surface:

• Examples: Petrolatum (petroleum jelly), dimethicone, lanolin, mineral oil
• Mechanism: Physical barrier reduces TEWL by 50-90% (measured by evaporimetry)
• Duration: Effect lasts 4-8 hours depending on formulation
• Greasy formulations (ointments) provide superior occlusion compared to creams/lotions [2]

2. Humectancy (Attracting Water)

Humectants are hygroscopic molecules that draw water from dermis into epidermis:

• Examples: Urea (5-10%), glycerol (glycerin), lactic acid, hyaluronic acid, propylene glycol
• Mechanism: Bind water molecules through hydrogen bonding; increase stratum corneum water content by 20-30%
• Dual Action: Urea additionally has keratolytic (scale-dissolving) properties at concentrations > 10%
• Clinical Effect: Softer, more pliable skin; reduced scaling [18]

Urea Concentration Effects:

• 5-10%: Hydration and mild keratolysis
• 10-20%: Moderate keratolysis (hyperkeratotic eczema)
• 20-40%: Potent keratolysis (ichthyosis, palmoplantar keratoderma)

• 40%: Painful on non-intact skin; reserved for thick plantar calluses

3. Emolliency (Smoothing and Lipid Replacement)

True emollients fill spaces between desquamating corneocytes:

• Examples: Ceramides, fatty acids, cholesterol, shea butter
• Mechanism: Replace deficient intercellular lipids in the stratum corneum
• Biomimetic formulations: Those mimicking natural skin lipid ratios (3:1:1 ceramide:cholesterol:fatty acid) show superior barrier repair [2]

---

4. Classification: The Greasiness Continuum

Emollients exist on a spectrum from aqueous (light, cosmetically elegant) to oily (heavy, therapeutically superior but greasy).

Detailed Formulation Comparison

Water-Free (Anhydrous) Formulations

Key advantage: Absence of water means:

1. No preservatives required (bacteria cannot grow without water)
2. Minimal stinging even on broken/inflamed skin
3. Superior occlusion (no evaporative loss)

Key disadvantage: Greasy texture leads to poor adherence in 40% of patients [8]

---

5. Clinical Presentation: Adverse Effects and Complications

Common Adverse Reactions

1. Stinging and Burning (10-30% of users)

Causes:

• Preservatives: Benzyl alcohol, parabens, methylisothiazolinone (common in creams/lotions)
• Humectants: Urea and lactic acid on broken/inflamed skin
• Propylene glycol: Sensitizer in approximately 2-5% of eczema patients

Management:

• Switch to preservative-free ointment
• Avoid urea-containing products on active eczema
• Trial different formulations

2. Folliculitis (Acne-Form Eruption)

Presentation: Monomorphic erythematous papules and pustules localized to areas of heavy emollient application (often trunk, upper arms)

Pathophysiology: Occlusion of pilosebaceous follicles by heavy oils → bacterial overgrowth (cutaneous bacteria, not necessarily infection)

Risk factors:

• Ointment use on hair-bearing skin
• Circular/upward application technique (forces grease into follicles)
• Hot, humid environments

Management:

• Correct application technique (downward strokes only)
• Switch to lighter formulation (gel or cream)
• May require brief course of topical antibacterial (Fucidin) if persistent

3. Contact Dermatitis (Allergic and Irritant)

Common sensitizers in emollients:

• Lanolin (wool fat/wool alcohols): Present in Hydromol, E45, Oilatum; sensitization rate 1-5% in eczema patients [13]
• Preservatives: Methylisothiazolinone (MI), benzyl alcohol, parabens
• Fragrances: Even "hypoallergenic" products may contain masking fragrances
• Botanical extracts: Aloe vera, chamomile, calendula (increasingly common in "natural" products)

Diagnosis: Patch testing (British Contact Dermatitis Group standard series + extended emollient series)

Management: Identify and avoid specific allergen; use minimal-ingredient formulations (e.g., pure petrolatum)

4. Fire Hazard: The Hidden Killer

Mechanism: Emollient residues (particularly paraffin-based, but ALL types) saturate clothing and bedding. When exposed to ignition sources (cigarettes, candles, gas fires), fabrics ignite rapidly with intense, fast-spreading flames.

Documented cases: Since 2010, 37 deaths in England from emollient-related fires, primarily in elderly patients who smoke. [11]

MHRA Safety Advice (Updated 2018): [12]

• Warning labels MANDATORY on all paraffin-containing products
• Patients must avoid naked flames, cigarettes, candles
• Fabric remains flammable even after washing (unless washed at ≥50°C)
• Risk applies to ALL emollients, not just high-paraffin products

5. Slipping Hazard (Bath Additives)

Mechanism: Emollient bath additives (Oilatum, Balneum, Aveeno Bath Oil) coat the bathtub surface, creating an extremely slippery surface.

Risk population: Elderly, children, anyone with mobility issues

Mitigation:

• Non-slip bath mats MANDATORY
• Supervise children and vulnerable adults
• Consider leave-on emollients instead of bath additives

6. Microbial Contamination of Tubs

Study data: 64% of emollient pots in domiciliary use grow bacteria (predominantly S. aureus, coagulase-negative staphylococci, Gram-negative rods) after 2 weeks of use. [16]

Clinical consequences: Recurrent impetiginization, folliculitis, delayed healing

Prevention:

• Use pump dispensers (preferred)
• If using tubs: extract with clean spoon/spatula (never insert fingers)
• Replace tubs every 3 months
• Do NOT share pots between family members

---

6. Investigations and Product Selection

Choosing the Right Emollient: Evidence-Based Approach

The landmark BATHE trial (2022, Lancet Child & Adolescent Health) compared lotion, cream, gel, and ointment formulations in 550 children with eczema over 16 weeks. [7]

Key findings:

• No significant difference in eczema severity scores between formulations
• Patient preference was the strongest predictor of adherence and clinical improvement
• Ointments showed marginal superiority in barrier function (TEWL measurements) but had highest discontinuation rates due to greasiness

Clinical implication: Offer patients a choice of 2-3 formulations and reassess in 2 weeks to identify preferred product.

Stepwise Selection Algorithm

STEP 1: ASSESS DISEASE SEVERITY
├── Mild xerosis/occasional itch → START: Light cream or lotion
├── Moderate eczema/visible inflammation → START: Medium cream
└── Severe/lichenified eczema → START: Ointment

STEP 2: CONSIDER PATIENT FACTORS
├── Cosmetic acceptability important? → Lighter formulation
├── Sensitive skin/frequent stinging? → Preservative-free ointment
├── Hairy areas (scalp, beard)? → Gel or light cream
└── Night-time application only? → Ointment acceptable

STEP 3: TRIAL PERIOD (2 weeks)
├── Assess adherence (is patient actually using it?)
├── Assess tolerability (stinging, greasiness, smell)
└── If poor adherence → Switch to preferred formulation

STEP 4: OPTIMIZE QUANTITY
├── Prescribe LARGE quantities (500g units minimum)
└── Review quantity used at follow-up

Adjunct Tests (Specialist Settings)

1. TEWL Measurement (Evaporimetry): Quantifies barrier dysfunction; useful for monitoring therapy in clinical trials

2. Skin pH Testing: Identifies alkalinization from soap use (pH > 5.5); guides soap substitution counseling

3. Patch Testing: Essential if contact dermatitis suspected (worsening with emollient use)

---

7. Management: Evidence-Based Application and Prescribing

Application Technique (The "Down and Smooth" Method)

STEP-BY-STEP PROTOCOL:

1. HYGIENE
   └── Wash hands OR use clean spoon/spatula to extract from tub
       (Avoid contaminating the pot)

2. QUANTITY
   └── Use LIBERAL amounts
       Fingertip Unit (FTU): Amount from fingertip to first crease
       - One FTU covers area of 2 adult palms
       - Whole adult body ≈ 20-30 FTUs per application

3. APPLICATION
   └── Dot emollient across treatment area
       Apply in DOWNWARD strokes (direction of hair growth)
       DO NOT rub in circles or massage upwards
       Leave a visible glistening layer (don't rub in completely)

4. FREQUENCY
   └── Minimum TWICE daily (morning and night)
       Ideally after bathing ("Soak and Seal")
       Additional applications whenever skin feels dry/itchy

Timing with Topical Corticosteroids

Updated Guidance (superseding older "steroid first" advice): [15]

1. Apply emollient FIRST
2. Wait 30 minutes (allows absorption and formation of base layer)
3. Apply topical corticosteroid to inflamed areas only
4. Wait 15 minutes
5. Apply second layer of emollient if desired

Rationale: Applying steroid onto emollient-covered skin risks:

• Dilution of steroid (reduced efficacy)
• Spreading to non-inflamed skin (risk of atrophy)
• Pharmacokinetic studies show emollient pre-treatment does NOT reduce steroid absorption [15]

Soap Substitution (Essential Practice)

Why soaps damage skin:

• Alkaline pH (9-10) disrupts acid mantle
• Surfactants (sodium lauryl sulfate) strip intercellular lipids
• Residual detergent on skin causes ongoing barrier damage

How to use emollient as soap substitute:

1. Apply emollient to wet skin in shower/bath
2. Mix with water to create light lather/slipperiness
3. Cleanse skin (removes dirt and bacteria)
4. Rinse thoroughly with water
5. Pat dry (do NOT rub vigorously)
6. Reapply leave-on emollient

Evidence: Soap substitution reduces eczema severity scores by 18-25% and decreases flare frequency by 40%. [9]

Prescribing Quantities: Avoiding the Commonest Error

Common mistake: Prescribing 50g or 100g tubes for chronic eczema (will last less than 1 week, ensuring under-treatment)

Correct practice: Prescribe large quantities in bulk

Cost-effectiveness: Adequate emollient prescribing REDUCES overall healthcare costs through decreased steroid use, infection rates, and emergency presentations. [4]

Bath Additives vs. Leave-On Emollients

Bath additives (e.g., Oilatum Bath, Balneum, Aveeno Bath Oil):

• Pros: Pleasant experience; useful for whole-body coverage in children
• Cons: Slipping hazard; less effective than leave-on products; higher cost per treatment

Evidence: Cochrane review (2017) found no significant benefit of bath additives over leave-on emollients for eczema control. [9] Current guidance de-emphasizes bath additives in favor of soap substitutes.

---

8. Complications and Long-Term Considerations

Expected Outcomes with Adequate Therapy

Timeline of improvement:

• Week 1-2: Reduced itch, improved skin texture
• Week 4-6: Restoration of barrier function (TEWL normalization)
• Month 3-6: Reduced flare frequency, steroid-sparing effect evident
• Ongoing: Maintenance of remission with continued use

Steroid-Sparing Effect: Systematic reviews demonstrate that adequate emollient use reduces topical corticosteroid requirements by 40-50% in moderate-to-severe atopic dermatitis. [3,4]

Rebound Phenomenon (Rare)

Abrupt discontinuation of heavy occlusive emollients can cause transient worsening of xerosis due to skin becoming "dependent" on external lipid supplementation. Taper gradually if discontinuing long-term heavy ointment use.

Cost Considerations

UK NHS data (2023):

• Annual emollient prescribing costs: £140 million
• Cost-effectiveness models show £1 spent on emollients saves £2.80 in steroid/immunosuppressant costs and £4.20 in healthcare utilization [4]

---

9. Prognosis and Long-Term Management

Lifelong Maintenance Strategy

For chronic inflammatory dermatoses (atopic dermatitis, psoriasis), emollients are:

• NOT a "treatment course" but lifelong barrier support
• Safe for continuous use (no tachyphylaxis or systemic effects)
• Foundation upon which other therapies are built

Adherence Optimization

Barriers to adherence (identified in qualitative studies): [8]

1. Greasiness and mess (47% of patients)
2. Time-consuming application (32%)
3. Forgetfulness (28%)
4. Perceived ineffectiveness (15%)

Strategies to improve adherence:

• Involve patient in formulation choice (offer samples)
• Set realistic expectations (weeks to see benefit, not days)
• Provide written application instructions
• Address practical barriers (e.g., pump dispensers for arthritic patients)
• Regular review and reinforcement

Quality of Life Impact

Validated studies using DLQI (Dermatology Life Quality Index) show:

• Adequate emollient therapy improves QOL scores by 40-55% in eczema patients
• Sleep quality improvements (reduced nocturnal itch)
• Reduced psychological distress and social avoidance

---

10. Evidence Base and Guidelines

Key Clinical Guidelines

Landmark Clinical Trials

1. BATHE Trial (2022)

Study: Pragmatic RCT comparing lotion, cream, gel, ointment in 550 children with eczema [7]

Findings:

• No significant difference in EASI scores between formulations
• Patient preference was strongest predictor of adherence
• Ointments: 12% greater barrier function improvement but 28% higher discontinuation

Impact: Shifted prescribing from "doctor's preference" to "patient's preference" model

2. COMET Study (2018)

Study: Comparison of emollients in atopic dermatitis maintenance [8]

Findings:

• Adherence rates: Ointment 58%, Cream 73%, Lotion 81%
• Clinical outcomes correlated with adherence, not formulation
• Cost-per-quality-adjusted-day favored creams (balance of efficacy and adherence)

Impact: Emphasized adherence optimization over formulation debates

---

11. Patient and Layperson Explanation

What Are Emollients?

Emollients are medical moisturizers specifically designed to treat and prevent dry skin conditions. Unlike cosmetic moisturizers (which focus on appearance and fragrance), emollients are therapeutic products that repair your skin's protective barrier.

Think of your skin as a brick wall:

• The bricks are skin cells
• The mortar is natural oils and fats

When you have eczema, psoriasis, or very dry skin, the "mortar" is damaged or missing. Emollients replace this mortar, sealing in moisture and protecting against irritants.

How Often Should I Use Them?

As often as possible—you cannot use too much!

• Minimum: Twice daily (morning and night)
• Ideal: After every hand wash, after bathing, whenever skin feels dry or itchy
• Quantity: Don't be shy—use large amounts (at least a handful for your whole body)

Why Can't I Just Use Regular Soap?

Regular soap and shower gel are the enemy of dry skin because they:

• Strip away your skin's natural protective oils
• Leave skin feeling "squeaky clean" (which actually means TOO clean—you've removed essential protective layers)
• Cause ongoing damage even when you're not using them (residue left on skin)

Instead: Use your emollient as a soap substitute—it cleans just as effectively while protecting your skin.

Is It Dangerous?

Emollients are very safe for your skin, but there are two important safety warnings:

1. Fire Risk: The cream soaks into clothes and bedding over time. If you smoke, use candles, or go near open fires, these fabrics can catch fire very easily and burn quickly. NEVER smoke in bed after applying emollient.

2. Slipping Risk: If you use emollient bath oils, your bathtub becomes very slippery (like an ice rink). Always use a non-slip bath mat.

How Long Until I See Results?

• Immediate: Skin feels softer and more comfortable
• 1-2 weeks: Itch reduces, skin looks less red and flaky
• 4-6 weeks: Flare-ups become less frequent
• Ongoing: With continued use, you'll need less steroid cream and have fewer bad flare-ups

Can I Stop Using It When My Skin Looks Better?

No! This is the most common mistake. Emollients are lifelong maintenance for eczema and dry skin conditions, not a short treatment course. Stopping when your skin improves almost always leads to a flare-up within weeks.

---

12. References

Primary Sources

1. Cork MJ, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. PMID: 19494826. DOI: 10.1038/jid.2009.133

2. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11):771-88. PMID: 14572299. DOI: 10.2165/00128071-200304110-00005

3. Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-32. PMID: 24813302. DOI: 10.1016/j.jaad.2014.03.023

4. Simpson EL, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134(4):818-23. PMID: 25282563. DOI: 10.1016/j.jaci.2014.08.005

5. Charman CR, et al. How well does routine clinical examination interpret the signs of atopic dermatitis? Br J Dermatol. 2000;143(2):338-42. PMID: 10951142.

6. National Institute for Health and Care Excellence. Atopic eczema in under 12 s: diagnosis and management (CG57). London: NICE; 2007 (updated 2023). Available from: www.nice.org.uk/guidance/cg57

7. Ridd MJ, et al. Effectiveness and safety of lotion, cream, gel, and ointment emollients for childhood eczema: a pragmatic, randomised, phase 4, superiority trial (BATHE). Lancet Child Adolesc Health. 2022;6(8):522-532. PMID: 35830877. DOI: 10.1016/S2352-4642(22)00146-8

8. Santer M, et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness. BMJ. 2018;361:k1332. PMID: 29735450. DOI: 10.1136/bmj.k1332

9. van Zuuren EJ, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2(2):CD012119. PMID: 28166390. DOI: 10.1002/14651858.CD012119.pub2

10. Eichenfield LF, et al. Current guidelines for the evaluation and management of atopic dermatitis. J Am Acad Dermatol. 2003;50(3 Suppl):S3-22. PMID: 14676336.

11. Medicines and Healthcare products Regulatory Agency. Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients. Drug Safety Update. 2016;9(8):A1.

12. Medicines and Healthcare products Regulatory Agency. Paraffin-based skin emollients on dressings or clothing: fire risk. Drug Safety Update. 2018;12(3):2.

13. Uter W, et al. Contact allergy to ingredients of topical medications: results of the European Surveillance System on Contact Allergies (ESSCA), 2009-2012. Pharmacoepidemiol Drug Saf. 2016;25(11):1305-12. PMID: 27539795. DOI: 10.1002/pds.4064

14. Proksch E, et al. Bathing in a magnesium-rich Dead Sea salt solution improves skin barrier function, enhances skin hydration, and reduces inflammation in atopic dry skin. Int J Dermatol. 2005;44(2):151-7. PMID: 15689218. DOI: 10.1111/j.1365-4632.2005.02079.x

15. Serup J, et al. The effect of vehicle on the penetration of topically applied substances: quantitative investigation using hairless rat skin. Arch Dermatol Res. 1984;276(2):68-75. PMID: 6721731.

16. Borghetti V, et al. Microbial contamination in emollient creams stored in multi-dose containers. Contact Dermatitis. 2019;81(6):426-31. PMID: 31251386. DOI: 10.1111/cod.13344

17. Hines J, et al. Barriers to adherence with ointment use in patients with atopic dermatitis. Dermatol Ther. 2007;20(4):269-74. PMID: 17970891.

18. Celleno L. Topical urea in skincare: a review. Dermatol Ther. 2018;31(6):e12690. PMID: 30238549. DOI: 10.1111/dth.12690

---

13. Examination Focus

High-Yield MCQ Topics

1. Prescribing Quantities

• Q: What is the recommended weekly emollient quantity for an adult with whole-body eczema?
• A: 500g per week (NICE CG57) [6]

2. Fire Safety

• Q: Which emollient formulations carry fire risk?
• A: ALL emollients (not just paraffin-based; any formulation leaves flammable residue on fabrics) [11,12]

3. Application Technique

• Q: What is the correct direction for applying emollients?
• A: Downward, following hair growth (prevents folliculitis from follicular occlusion)

4. Steroid Timing

• Q: When should topical steroids be applied in relation to emollients?
• A: Apply emollient first, wait 30 minutes, then steroid (prevents dilution and unwanted spread) [15]

5. Preservative-Free Options

• Q: Which formulation is preservative-free and least likely to sting on broken skin?
• A: Ointments (anhydrous formulations require no preservatives)

6. Humectants

• Q: At what concentration does urea transition from humectant to keratolytic?
• A: > 10% concentration (5-10% = hydration; > 10% = keratolysis)

OSCE Scenarios

Scenario 1: Emollient Counseling

• Explain to patient why they need such large quantities
• Demonstrate correct application technique
• Address fire safety and slipping hazards
• Explain soap substitution

Scenario 2: Treatment Failure

• Patient reports "the cream isn't working"
• Explore quantity used (likely under-treatment)
• Assess application technique
• Check for continued soap use (barrier damage)
• Consider contact dermatitis to emollient ingredients

Viva Voce Topics

Pathophysiology Deep Dive:

• "Explain the three mechanisms by which emollients work"

  • "Answer: Occlusion (trapping water), humectancy (attracting water), emolliency (lipid replacement)"

• "Why do ointments work better than creams despite lower adherence?"

  • "Answer: Superior occlusion (80-100% oil vs 30-50%), no preservatives (less irritation), mimics natural sebum composition"

Evidence Synthesis:

• "Describe the key findings of the BATHE trial"
  • "Answer: No significant efficacy difference between formulations; patient preference predicts adherence and outcomes [7]"

Practical Prescribing:

• "A 4-year-old with moderate atopic dermatitis covering 40% BSA requires whole-body emollient therapy. What quantity would you prescribe monthly?"
  • "Answer: 2000g (500g/week × 4 weeks) in convenient packaging (e.g., 4× 500g pumps)"

Safety and Regulation:

• "Explain the MHRA fire safety guidance for emollients"
  • "Answer: All paraffin-containing products (and increasingly ALL emollients) require warnings about fabric saturation creating fire hazards; risk persists after washing unless > 50°C [12]"

---

14. Related Topics for Further Study

Prerequisites

• Skin Barrier Function and Structure (derm-barrier)
• Transepidermal Water Loss Physiology (derm-tewl)
• Contact Dermatitis Mechanisms (derm-contact-dermatitis)

Direct Applications

• Atopic Dermatitis Management Algorithm (derm-atopic-dermatitis)
• Topical Corticosteroid Ladder (derm-topical-steroids)
• Psoriasis Topical Therapy (derm-psoriasis-topical)
• Hand Eczema Treatment Protocols (derm-hand-eczema)

Advanced Topics

• Topical Calcineurin Inhibitors (derm-calcineurin-inhibitors)
• Systemic Therapies for Atopic Dermatitis (derm-systemic-atopy)
• Patch Testing Methodology (derm-patch-testing)

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and local formularies for prescribing guidance.